Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins
Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins
复制标题
DOI：
10.1016/j.jaci.2009.08.018
复制
发表时间：
2010-02-01
影响因子：
14.2
通讯作者：
Kavanaugh, Arthur
中科院分区：
文献类型：
--
作者：
Lee, Susan J.;Chinen, Javier;Kavanaugh, Arthur
免疫系统由存在于复杂网络中的多种免疫活性细胞和炎症介质组成。这些成分通过级联和反馈电路相互作用，维持生理炎症（例如组织修复）和免疫监视。在各种自身免疫和过敏性疾病中，外来抗原或自身抗原可能会破坏这种良好的平衡，导致免疫失调、持续炎症，并最终导致病理后遗症。近年来，在描述免疫系统的特定组成部分方面取得了巨大进展，这些组成部分有助于正常免疫和特定疾病状态的各个方面。随着对发病机制有了更深入的了解，加上生物技术的进步，许多通常被称为“生物制剂”的免疫调节剂已被引入临床，用于治疗各种病症，包括免疫球蛋白和细胞因子。最常见的两类已批准的生物制剂是单克隆抗体和具有精确特异性的融合蛋白。与不太具体的免疫抑制方法相比，这些药物有潜力通过更彻底地调节失调的免疫反应的特定部分来优化结果，并最大限度地减少毒性。（J Allergy）临床免疫学 2010；125：S314-23。）
The immune system consists of a diverse array of immunocompetent cells and inflammatory mediators that exist in complex networks. These components interact through cascades and feedback circuits, maintaining physiologic inflammation (eg, tissue repair) and immunosurveillance. In various autoimmune and allergic diseases, a foreign antigen or autoantigen might upset this fine balance, leading to dysregulated immunity, persistent inflammation, and ultimately pathologic sequelae. In recent years, there has been tremendous progress delineating the specific components of the immune system that contribute to various aspects of normal immunity and specific disease states. With this greater understanding of pathogenesis coupled with advances in biotechnology, many immunomodulatory agents commonly called "biologic agents'' have been introduced into the clinic for the treatment of various conditions, including immune globulins and cytokines. The 2 most common classes of approved biologic agents are mAbs and fusion proteins with exquisite specificity. These agents have the potential both to optimize outcomes through more thorough modulation of specific parts of the dysregulated immune response and to minimize toxicity compared with less specific methods of immunosuppression. (J Allergy Clin Immunol 2010;125:S314-23.)